



MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

June 17, 2026

CAMBRIDGE, Mass., June 17, 2026 /PRNewswire/ -- **MetaVia Inc.** (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Wednesday, June 24, 2026 at 10:30 am ET.



This will be a live, interactive online forum where investors are invited to ask the company questions in real-time. If attendees are not able to join the live event on the day of the conference, an archived webcast will also be made available after the conclusion of the forum.

It is recommended that investors pre-register using this [link](#) and run the online system check to expedite participation and receive event updates.

MetaVia will be available for one-on-one meetings; investors may register using this [link](#). To schedule a meeting with management outside of the conference, please contact Michael Miller at mmiller@rxir.com.

About MetaVia

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP-1 receptor agonists such as semaglutide. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a potential first-in-class drug candidate targeting G-protein-coupled receptor 119 (GPR119). In preclinical studies, vanoglipel demonstrated a positive metabolic effect on glucose and lipid control, and also proved differentiated hepatic benefits reducing hepatic steatosis, hepatic inflammation, and liver fibrosis regardless independent of metabolic improvement. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com.

Contacts:

MetaVia

Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

[Rx Communications Group](#)

Michael Miller
+1-917-633-6086
mmiller@rxir.com

 View original content: <https://www.prnewswire.com/news-releases/metavia-to-highlight-novel-obesity-and-metabolic-therapies-at-upcoming-life-sciences-virtual-investor-forum-302803076.html>

SOURCE MetaVia Inc.